Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

What Future For Genentech's Lebrikizumab On Phase III Failure?

This article was originally published in Scrip

Executive Summary

Roche/Genentech's IL-13 inhibiting investigational severe asthma product lebrikizumab has failed in one of its two pivotal trials, adding to reservations about its future. Lebrikizumab is already trailing other biological competitors to the market and the lack of robust data at Phase III could well spell the end in this indication.

Advertisement

Related Content

Teva Gets EU Green Light For Reslizumab
AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience

Topics

Advertisement
UsernamePublicRestriction

Register